Real-world study of pluvicto in advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This study looks at how well Pluvicto, a targeted radiation therapy for advanced prostate cancer, works in real-world patients. It aims to learn more about survival outcomes for people like you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with prostate cancer that has spread to other parts of the body (metastatic).
- You are male and 18 years of age or older.
- You have received treatment with Pluvicto (a type of targeted radiation therapy for advanced prostate cancer).
- You have not had another type of cancer (other than prostate cancer) in the past 3 years.
- You are not currently participating in another clinical trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at people with advanced prostate cancer that has stopped responding to hormone therapy and chemotherapy. It tests a radioactive medicine (lutetium-177 PSMA) that targets prostate cancer cells, to see what factors predict a good response.
This study looks at real-world data from patients with metastatic castration-resistant prostate cancer (mCRPC) who have already used certain treatments, including a newer drug called lutetium-177 PSMA-617. It aims to understand how these treatments work and what happens to patients over time.
This study looks at how men with advanced prostate cancer (mCRPC) do when they receive a treatment called Pluvicto (lutetium vipivotide tetraxetan) in real-world settings. It aims to collect information on treatment effectiveness and quality of life without adding any extra procedures or medications.
This trial studies how well a radioactive drug called Pluvicto works in men with prostate cancer who also have kidney or bone marrow problems. You'll get the treatment and have several scans to see how the drug affects your body.
This trial tests whether the drug Pluvicto (also known as lutetium Lu 177 vipivotide tetraxetan) can help African American men with a type of prostate cancer that has spread and no longer responds to hormone therapy. The treatment targets a protein called PSMA found on cancer cells, which may slow the cancer's growth.
This study is for men with prostate cancer who are being treated with or are scheduled to receive the drug Pluvicto in South Korea. It aims to track real-world results and safety.
Hear when a new Prostatic Neoplasms, Castration-Resistant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.